Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (20714)	5/13/1998 8:16:00 PM
From: Mudcat	Read Replies (2) \| Respond to of 32384

<Let me think about the merits of your statement for a little while.> Read what I said. The estimate did not pass the common sense test when it came out because when a company goes from negative earnings to +.84 in one year this should be a big deal and a strong buy rec should have been made. When the .84 was announced no change in rec was made (first hint something was wrong). Then when the estimate was announced it had no effect on the stock price (second hint). And now when the estimate was lowered, very little change in price (3rd hint). The small change today I attribute to the SRGN deal. Maybe you shouldn't always believe what the analyst say without giving it the common sense test. Seems like this analyst saw his mistake and corrected it. I'm surprised he lowered his estimate with Lgnds comments that the SRGN deal will help boost 99 earnings.